fbpx

3M Earplug Hearing Loss Trial Scheduled for Spring 2021

3M is currently facing over 200,000 product liability lawsuits in the federal court system, all involving similar allegations that the company distributed defective Combat Arms earplugs that left military service members at risk for permanent hearing loss, tinnitus (the perception of ringing), and other issues. The first trial, which involves three separate claims from veterans, is scheduled to go before one jury in April 2021.

The 3M Combat Arms earplug version 2 (CAEv2) was issued to all U.S. military service members from 2003 to 2015. Thanks to the dual-ended or reversible design, the earplugs were meant to block all sound when inserted one way and provide selective filtering when inserted the other way (i.e. reduce loud, potentially-damaging sounds but allow spoken commands). 

The lawsuits all raise similar allegations that 3M failed to share critical safety information and necessary instructions for proper use with the U.S. government. Given the similar natures of the lawsuits, federal multi-district litigation (MDL) was created last year, centralizing the claims before U.S. District Judge Casey Rodgers in Florida and allowing for coordinated discovery and pretrial proceedings.

Although these outcomes will not be binding for future plaintiffs, they will be closely watched to determine how juries may respond to the evidence that links the 3M earplugs to hearing loss and other problems. They may also have a major impact on potential settlement negotiations. 

Bayer Issues New Proposed Settlement in Cases Linking Roundup to Lymphoma Cancer

Multiple jury verdicts in the Bay Area confirmed the link between the widely-used herbicide Roundup (a Monsanto product) and lymphoma cancer, and now, parent company Bayer is hoping to resolve future lawsuits with a proposed $2 billion settlement — its second attempt at reaching an agreement. Product users who were later diagnosed with non-Hodgkin’s lymphoma would receive up to $200,000 in compensation — or more in “exceptional circumstances.” The settlement would remain ongoing for four years, but a judge could approve additional time and/or increase the $2 billion budget if both sides requested the change. 

The settlement is still waiting for approval from a federal judge in San Francisco, who criticized Bayer’s first attempt at settling. Last summer, Bayer and a group of plaintiffs’ lawyers were sent back to the drawing board after being denied their proposed $1.25 billion agreement. 

Not only is the new version financially larger, but it is also less restrictive, allowing non-participants more freedom to pursue their cases in court with only some limitations on damages. Additionally, the settlement would add information to Roundup’s label, saying it may cause non-Hodgkin’s lymphoma, an often deadly cancer. While the label would not directly state Roundup as a cause of the disease, it would include a link to information related to both sides of the legal battle. It would also provide Monsanto product users with free medical evaluations and legal advice as needed. 

In another new section of the settlement, a group of scientists will be chosen by Bayer and the plaintiffs’ lawyers to conduct an independent study on Roundup’s active ingredient, glyphosate, and its links to cancer. Although the U.S. Environmental Protection Agency has declared the product safe, the International Agency for Research on Cancer, part of the World Health Organization, determined in 2015 that glyphosate was a probable cause of human cancer. 

Bayer previously settled up to 125,000 suits with a nearly $10 billion agreement, all directed at U.S. residents who said they had been diagnosed with cancer or other illnesses after using Roundup or Ranger Pro, another product that contained glyphosate. 

Roundup

Consumer Fraud Claims for Makers of Generic Valsartan Blood Pressure Drugs

In New Jersey, on Friday, January 29, 2021, U.S. District Judge Robert Kugler permitted numerous fraud allegations to move forward against a group of generic blood pressure drugmakers that consumers claim consciously sold their valsartan medications with the presence of possible carcinogen N-nitrosodimethylamine (NDMA). The companies in question include but are not limited to: China’s Zhejiang Huahai Pharmaceutical, Prinston Pharmaceutical, Hetero Drugs, Mylan, Aurobindo Pharma, Teva, Arrow Pharm Malta, and Actavis Pharma.

In 2018, the FDA discovered that NDMA and the similar N-nitrosodiethylamine (NDEA) could be created during the manufacturing of certain drugs. The results led to a global recall of hundreds of lots of blood pressure drugs valsartan, irbesartan, and losartan. The FDA then launched a thorough investigation into how the contamination may have occurred as well as the risk it could present for U.S. consumers. 

Buyers hope to hold the companies responsible for the recall of drugs containing valsartan, which is the active ingredient in Novartis’ Diovan, due to a failure to mention the potential presence of NDMA. According to the lawsuit, the plaintiffs believe that the drugmakers would have found the NDMA impurities sooner had they followed FDA guidelines, suggesting that the manufacturers “either knew of or recklessly disregarded the contamination,” according to Ruben Honik, an attorney for the consumers. 

Judge Kugler simultaneously threw out claims against distributors of the generic drugs, claiming that wholesalers Cardinal Health, McKesson, and AmerisourceBergen as well as pharmacies including CVS Health, Walgreens Boots Alliance, and Rite Aid couldn’t have known that they were stocking tainted products. 

Bayer Roundup Claims

Bayer will be paying $10.5 billion to settle U.S. claims that Roundup, its weedkiller, has lead to cancer in nearly 100,000 patients.

Bayer AG introduced on Wednesday it struck an about $10.5 billion deal to work out countless claims with U.S. complainants affirming the firm’s Roundup herbicide causes cancer. Wednesday’s deal complies with months of talks between Bayer and also plaintiffs’ lawyers.

Bayer, which additionally makes pharmaceuticals, inherited countless legal actions against Roundup’s developer Monsanto Co. when it acquired the U.S. farming titan in 2018. Bayer has actually argued that Roundup is safe and also has repetitively protected the Monsanto bargain.

As part of the case, Bayer will pay some $9.5 billion to settle claims brought by attorneys standing for some 95,000 plaintiffs. It will set aside an added roughly $1.1 billion to establish and fund a panel to examine whether the item causes cancer cells to support future cases.


Bayer to pay $10.5B to settle 100,000 Roundup cancer claims in US

Politico

Bayer has agreed to pay about $10.5 billion to settle claims in the U.S. that its weedkiller Roundup led to cancer in nearly 100,000 patients exposed to the popular herbicide, according to a law firm representing some of the plaintiffs.

Read More >>


Bayer to Pay Up to $10.9 Billion to Settle Lawsuits Over Roundup Weedkiller

Wall Street Journal

Bayer AG said Wednesday it would pay up to $10.9 billion to settle tens of thousands of lawsuits with U.S. plaintiffs alleging the company’s Roundup herbicide causes cancer, a milestone in the German company’s legal battle that has been weighing down its share price for nearly two years.

Read More >>

Roundup Maker to Pay $10 Billion to Settle Cancer Suits

The New York Times

Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin’s lymphoma. Some of the money is set aside for future cases.

Read More >>


Bayer agrees to pay $10 billion to settle Roundup weedkiller cancer claims

Axios

Bayer has agreed to pay just over $10 billion in order to settle roughly 125,000 claims that its Roundup weedkiller cases cancer and resolve potential future litigation, the company announced on Wednesday.

Read More >>


Bayer reaches $10.5 billion Roundup settlement

Market Watch

Bayer AG is set to announce on Wednesday it struck a roughly $10.5 billion deal to settle tens of thousands of lawsuits with U.S. plaintiffs alleging the company’s Roundup herbicide causes cancer, a milestone in the German company’s legal battle that has been weighing down its share price for nearly two years, according to a person familiar with the deal.

Read More >>


Have you or a loved one been impacted by Roundup?

Contact us below to learn about your options.

Free Drug and Medical Device Case Review
First
Last
Described what happened to you, we will review and reach out to you about your situation.
Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.